Guidance on applications for COVID-19 drug clinical trials under the Regulations: Post-authorization requirements

Guidance on applications for COVID-19 drug clinical trials under the Regulations: Post-authorization requirements This section of the guidance outlines requirements for the licence holder after authorization of the clinical trials. 2023-10-28 Health Canada open-ouvert@tbs-sct.gc.ca Health and Safetyguidance for applicantsseeking authorizationdrug-clinical-trialsconduct COVID-19 drug-clinical-trialsthe Regulationspost-authorization requirements Guidance on applications for COVID-19 drug clinical trials under the Regulations: Post-authorization requirements HTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/clinical-trials/covid-19-regulations/post-authorization-requirements.html Guidance on applications for COVID-19 drug clinical trials under the Regulations: Post-authorization requirements HTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/essais-cliniques/covid-19-reglement/exigences-apres-autorisation.html

This section of the guidance outlines requirements for the licence holder after authorization of the clinical trials.

Data and Resources

Similar records